The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intelligence approaches

Abstract

Background Risk stratification or progression in prostate cancer is performed with the support of clinical-pathological data such as the sum of the Gleason score and serum levels PSA. For several decades, methods aimed at the early detection of prostate cancer have included the determination of PSA serum levels. The aim of this systematic review is to provide an overview about recent advances in the discovery of new molecular biomarkers through transcriptomics, genomics and artificial intelligence that are expected to improve clinical management of the prostate cancer patient. Methods An exhaustive search was conducted by Pubmed, Google Scholar and Connected Papers using keywords relating to the genetics, genomics and artificial intelligence in prostate cancer, it includes “biomarkers”, “non-coding RNAs”, “lncRNAs”, “microRNAs”, “repetitive sequence”, “prognosis”, “prediction”, “whole-genome sequencing”, “RNA-Seq”, “transcriptome”, “machine learning”, and “deep learning”. Results New advances, including the search for changes in novel biomarkers such as mRNAs, microRNAs, lncRNAs, and repetitive sequences, are expected to contribute to an earlier and accurate diagnosis for each patient in the context of precision medicine, thus improving the prognosis and quality of life of patients. We analyze several aspects that are relevant for prostate cancer including its new molecular markers associated with diagnosis, prognosis, and prediction to therapy and how bioinformatic approaches such as machine learning and deep learning can contribute to clinic. Furthermore, we also include current techniques that will allow an earlier diagnosis, such as Spatial Transcriptomics, Exome Sequencing, and Whole-Genome Sequencing. Conclusion Transcriptomic and genomic analysis have contributed to generate knowledge in the field of prostate carcinogenesis, new information about coding and non-coding genes as biomarkers has emerged. Synergies created by the implementation of artificial intelligence to analyze and understand sequencing data have allowed the development of clinical strategies that facilitate decision-making and improve personalized management in prostate cancer.

Liquid Biopsy in Prostate Cancer Management—Current Challenges and Future Perspectives

“…Recently, novel small non-coding RNAs have been investigated as promising diagnostic biomarkers for PCa patients [99,100]. Small RNA harbored by extracellular vesicles (EVs) could be considered a valuable marker for PCa diagnosis.…”

Proteomic Analysis of Prostate Cancer FFPE Samples Reveals Markers of Disease Progression and Aggressiveness

“…In addition, Promark, which is an 8-marker assay (certified by Clinical Laboratory Improvement Amendments—CLIA) that predicts PCa aggressiveness, is based on a quantitative multiplex proteomics imaging (QMPI) approach [ 17 ]. Apart from proteomics, transcriptomics approaches have had a significant contribution to the discovery of PCa biomarkers, as well [ 40 , 41 , 42 ].…”

Accurate prognosis for localized prostate cancer through coherent voting networks with multi-omic and clinical data

“…Alarcón-Zendejas et al 64 and Goldenberg et al 65 review recent advances in biomarker discovery for prostate cancer, indicating ML-based and AI-based approaches as opening a new dimension to research and opportunities for transferring new computational techniques in clinical practice in this area. In our work, we push this view by extending the novel ML paradigm of the Coherent Voting Networks (CVN) with improved model selection techniques, and by applying it to the challenging problem of the prognosis of prostate cancer at a fine time granularity (year-to-year).…”

“…Role of AI and ML in biomarker discovery. Alarcón-Zendejas et al 64 and Goldenberg et al 65 Prognosis based on gene expression and proteomic data. We use mainly mRNA gene expression data sets obtained via high throughput assays as the primary source for prognostic biomarker discovery and validation.…”